ADA 2026 delivered a massive wave of obesity and diabetes data, and in this episode of On The Pen, Dave Knapp (@manonthemounjaro) sits down witH ​⁠ to break down the molecules, clinical trials, weight loss results, and safety signals that could define the next generation of obesity and diabetes medicine. We dive deep into Survodutide, Mazdutide, UBT251, Berobenatide (MET-097), CagriSema, Zenagamtide (formerly Amycretin), Petrelintide, and so much more! From GLP-1/glucagon dual agonists to triple agonists targeting GLP-1, GIP, and glucagon, the obesity treatment landscape is becoming more competitive than ever. Which therapies showed the strongest weight loss? Which struggled with tolerability? And what do these results mean for patients living with obesity, type 2 diabetes, MASLD, sleep apnea, and other metabolic diseases? In this episode: ✅ Survodutide obesity and liver fat reduction data ✅ Mazdutide Phase 3 obesity and diabetes results ✅ UBT251 triple agonist weight loss data ✅ Berobenatide (MET-097) long-acting GLP-1 updates ✅ CagriSema diabetes and obesity trial results ✅ Zenagamtide (Amycretin) injectable and oral development ✅ Petrelintide amylin agonist info ✅ Future GLP-1, GIP, glucagon, and amylin therapies The future of obesity medicine is no longer just about who produces the most weight loss. It’s about matching the right therapy to the right patient, improving tolerability, and addressing metabolic disease beyond the number on the scale. Read more obesity medicine news at obesity.news 🔗 Linktree: linktr.ee/manonthemounjaro #ADA2026 #Retatrutide #CagriSema #Survodutide #Mazdutide #UBT251 #Berobenatide #MET097 #Zenagamtide #Amycretin #Petrelintide #Inisepatide #Elcaglipron #GLP1 #ObesityMedicine #WeightLoss #Type2Diabetes #Zepbound #Mounjaro #Wegovy #GLP1News #ObesityResearch #DiabetesResearch #OnThePen

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

On The Pen GLP-1 News

# Full Transcript

**Podcast:** On The Pen GLP-1 News

## Transcript

If you've been following our ADA coverage, you'll remember today's guest just before the ADA conference here in 2026. Jen, better known as Jen Kanush over on X, joined us to preview a lot of the molecules and studies and companies that she believed would be sort of the most impactful to the On The Pen community. Well, ADA came and went and it came with a deluge of information. The data was presented and the debates have already started over on X.

We've seen new phase three results, new obesity and diabetes data, some surprising safety signals along the way. And maybe some of the most important information was that we have this growing realization that the next generation of obesity medicine is going to be a lot more complicated than simply asking who produces the most powerful drug.

And today we're going to bring Jen back to separate the signal from the noise that we heard at ADA 2026 and help us understand what really mattered. Welcome back to On The Pen. You're about to be injected with the highest dose of information, empowerment and inspiration. The On The Pen live experience has arrived.

Get ready to embark on a transformative adventure. Welcome to On The Pen live. Welcome back to On The Pen live, this special edition as we round up ADA 2026. We're so glad to have you here. I'm your host, Dave Knapp, man on the Majora. That's why I'm here. You are on the pen. We go be Saxenda, Victoza, Trulicity, Majora, Zetbound, Compound, that pen.

And it's what we talk about literally every week here as we empower you to have better conversations with your medical providing team. And this is going to be a great episode. But if you're just tuning in here for the first time and you're thinking, what is all this hubbub about GLP-1s, the pills, the shots? Is it cheating? Am I going to have to be on it forever? Well, just buckle up. Stick around for a little bit because we cover everything about obesity medicine here. And we think that you're going to really enjoy the content that we put out here.

So hit subscribe, hit the bell for notification, and there's a little hype button down below. If you're watching on a mobile app, you hit that hype button. It's going to send this out to a whole bunch of new people who could potentially use this information to better their lives. Now, if you're the type of person who's talked to your doctor about obesity medicine and you got kind of a side eye or, or, I don't know what to think about those drugs. You just need to check out our partners at Shed. Because Shed intrinsically understands that obesity is a chronic relapsing and multifactorial disease.

And they have the solutions and experts to help point you in the right direction of the care that might be most appropriate to you. And the bonus is if you check out Shed and use code OTP25, you're going to save 25% on obesity care at Shed. So visit Trished.com today. Use code OTP25. And make sure you...

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

Transcript

Built for investment professionals

Every day you wait, your competitors are finding
edge in conversations you're not hearing.

What Comes After Zepbound? The Biggest ADA 2026 Obesity Drug Breakthroughs

Transcript

Built for investment professionals

Every day you wait, your competitors are findingedge in conversations you're not hearing.

Every day you wait, your competitors are finding
edge in conversations you're not hearing.